ATTAIN STUDY ACLIDINIUM PDF

ATTAIN STUDY ACLIDINIUM PDF

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Datilar Tygogor
Country: Kosovo
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 24 December 2016
Pages: 203
PDF File Size: 3.35 Mb
ePub File Size: 12.77 Mb
ISBN: 372-9-68661-650-9
Downloads: 1549
Price: Free* [*Free Regsitration Required]
Uploader: Milmaran

Efficacy and safety Aclidinium has been extensively evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review. Expert Opin Drug Deliv. N Engl J Med.

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Discussion As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient.

Cochrane Database Syst Rev. Inhaler mishandling remains common in real life and is associated with reduced disease control. Mean area under the FEV 1 curve 0—24 h time interval was 1.

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Data reported as least squares mean standard error. Published online Mar Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated ] [Accessed December 12, atfain.

Well tolerated, no anticholinergic side effects reported, no clinical effect on EKG parameters.

While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.

A phase I, open-label, single-dose clinical trial. Safety and tolerability of aclidinium bromide in patients with COPD: However, these studies were not designed to directly compare the two doses, and confidence intervals often overlapped. Aclidinium bromide for stable chronic obstructive pulmonary disease.

  KARAK AZGAL PDF

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Alidinium to peer review, Almirall S. Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: In continuation studies, these improvements were sustained for up to 52 weeks.

However, the rate of decline in FEV 1 — the primary outcome of the trial — was not significantly reduced by the use of tiotropium. European Medicines Agency; Phase II Joos et al Glycopyrronium bromide Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. Aclidinium has been extensively evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review.

Adverse events reported by seven patients receiving aclidinium, eight receiving placebo, and three receiving tiotropium Most common AE was COPD exacerbation three patients all receiving placebo. The safety profile of aclidinium was comparable to placebo.

COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)

Furthermore, a higher proportion of patients treated with aclidinium achieved the MCID in each of these measures, compared with placebo. As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient.

Reproduced with permission of the European Respiratory Society: Minimal clinically important differences in COPD lung function. Stuyd J Clin Pharmacol Ther. Subsequently, studies investigating higher doses and alternative dosing regimens were conducted, 2930 leading to two Phase III studies: Phase II Chanez et al Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: This article has been cited by other articles in PMC.

  ENVIRONMENTAL BIOTECHNOLOGY RITTMAN PDF

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. The BID dosing does not appear to be a disadvantage compared to the QD regimes of tiotropium and glycopyrronium, since it may confer attaiin overnight bronchodilation that may be particularly beneficial for patients with significant night and morning symptoms.

The author reports no other conflicts of interest in this work. That may be the case with aclidinium.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide. Abstract Three aclidinuim muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease.

US Food and Drug Administration; In the pivotal Phase III clinical stury, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks.

Support Center Support Center. Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials. What stands out as the difference between it and them, since they seem to stduy similar efficacy and safety profiles? Dosing regimens and inhaler performance may be equally important in determining relative advantages of one drug over another.

Pharmacokinetic studies in healthy volunteers showed that it is poorly absorbed into plasma and stufy hydrolyzed into two major inactive metabolites, resulting in limited systemic exposure.